Recommended Topic Related To:

Zemaira

"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...

Zemaira

Side Effects
Interactions

SIDE EFFECTS

Intravenous administration of Zemaira (alpha-proteinase inhibitor (human)) , 60 mg/kg weekly, has been shown to be generally well tolerated. In clinical studies, the following treatment-related adverse reactions were reported: asthenia, injection site pain, dizziness, headache, paresthesia, and pruritus. Each of these related adverse events was observed in 1 of 89 subjects (1%). The adverse reactions were mild.

Should evidence of an acute hypersensitivity reaction be observed, the infusion should be stopped promptly and appropriate countermeasures and supportive therapy should be administered.

Table 3 summarizes the adverse event data obtained with single and multiple doses during clinical trials with Zemaira (alpha-proteinase inhibitor (human)) and Prolastin®. No clinically significant differences were detected between the two treatment groups.

Table 3: Summary of Adverse Events

 

Zemaira

Prolastin®

No. of subjects treated

89

32

No. of subjects with adverse events regardless of causality (%)

69 (78%)

20 (63%)

No. of subjects with related adverse events (%)

5 (6%)

4 (13%)

No. of subjects with related serious adverse events

0

0

No. of infusions

1296

160

No. of adverse events regardless of causality (rates per infusion)

298 (0.230)

83 (0.519)

No. of related adverse events (rates per infusion)

6 (0.005)

5 (0.031)

The frequencies of adverse events per infusion that were ≥0.4% in Zemaira (alpha-proteinase inhibitor (human)) -treated subjects, regardless of causality, were: headache (33 events per 1296 infusions, 2.5%), upper respiratory infection (1.6%), sinusitis (1.5%), injection site hemorrhage (0.9%), sore throat (0.9%), bronchitis (0.8%), asthenia (0.6%), fever (0.6%), pain (0.5%), rhinitis (0.5%), bronchospasm (0.5%), chest pain (0.5%), increased cough (0.4%), rash (0.4%), and infection (0.4%). The following adverse events, regardless of causality, occurred at a rate of 0.2% to <0.4% per infusion: abdominal pain, diarrhea, dizziness, ecchymosis, myalgia, pruritus, vasodilation, accidental injury, back pain, dyspepsia, dyspnea, hemorrhage, injection site reaction, lung disorder, migraine, nausea, and paresthesia.

Diffuse interstitial lung disease was noted on a routine chest x-ray of one subject at Week 24. Causality could not be determined.

In a retrospective analysis, during the 10-week blinded portion of the 24-week clinical study, 6 subjects (20%) of the 30 treated with Alpha1-Proteinase Inhibitor (Human), Zemaira (alpha-proteinase inhibitor (human)) had a total of 7 exacerbations of their chronic obstructive pulmonary disease (COPD). Nine subjects (64%) of the 14 treated with Prolastin® had a total of 11 exacerbations of their COPD. The observed difference between groups was 44% (95% confidence interval from 8% to 70%). Over the entire 24-week treatment period, of the 30 subjects in the Zemaira (alpha-proteinase inhibitor (human)) treatment group, 7 subjects (23%) had a total of 11 exacerbations of their COPD.

Read the Zemaira (alpha-proteinase inhibitor (human)) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

No information available.

 

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

Side Effects
Interactions
A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD